Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS

Aberdeen Group plc raised its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 52.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 304,609 shares of the medical research company’s stock after acquiring an additional 105,138 shares during the quarter. Aberdeen Group plc owned about 0.16% of Exact Sciences worth $16,665,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Assetmark Inc. grew its position in shares of Exact Sciences by 7.2% in the third quarter. Assetmark Inc. now owns 3,588 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 242 shares in the last quarter. Illinois Municipal Retirement Fund boosted its stake in Exact Sciences by 20.1% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 97,134 shares of the medical research company’s stock worth $5,314,000 after purchasing an additional 16,264 shares during the period. Skylands Capital LLC grew its holdings in Exact Sciences by 54.1% during the 3rd quarter. Skylands Capital LLC now owns 32,175 shares of the medical research company’s stock valued at $1,760,000 after buying an additional 11,300 shares in the last quarter. Krilogy Financial LLC increased its position in shares of Exact Sciences by 30.7% during the third quarter. Krilogy Financial LLC now owns 55,845 shares of the medical research company’s stock valued at $3,055,000 after buying an additional 13,129 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in shares of Exact Sciences in the third quarter worth about $4,139,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Up 0.0%

NASDAQ:EXAS opened at $103.36 on Thursday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.44 and a current ratio of 2.43. The firm has a market cap of $19.73 billion, a P/E ratio of -93.96, a P/E/G ratio of 2.35 and a beta of 1.42. Exact Sciences Corporation has a fifty-two week low of $38.81 and a fifty-two week high of $103.54. The firm has a 50-day simple moving average of $102.23 and a two-hundred day simple moving average of $76.93.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.29). The firm had revenue of $878.38 million for the quarter, compared to the consensus estimate of $860.59 million. Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. Exact Sciences’s revenue was up 23.1% on a year-over-year basis. During the same period last year, the business earned ($0.06) EPS. Analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Barclays reaffirmed an “equal weight” rating and set a $105.00 price objective (up previously from $77.00) on shares of Exact Sciences in a research note on Thursday, November 20th. Wall Street Zen lowered shares of Exact Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Jefferies Financial Group downgraded Exact Sciences from a “buy” rating to a “hold” rating and increased their price objective for the stock from $90.00 to $105.00 in a research report on Monday, November 24th. Zacks Research lowered Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Finally, Craig Hallum cut shares of Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 target price on the stock. in a report on Friday, November 21st. Two investment analysts have rated the stock with a Buy rating, twenty-one have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Exact Sciences presently has an average rating of “Hold” and a consensus price target of $89.56.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.